CSF2 and neoplasm: Subsequent to that, they showed that HER2/neu transgenic mice treated sequentially with neu-specific monoclonal antibodies and a neu-targeted GM-CSF secreting whole cell vaccine could overcome immune tolerance leading to improvements in tumor-free survival over either modality alone [12].